Balixafortide

DRUG2 trials

Sponsors

Spexis AG, Arsen Osipov

Conditions

Locally Recurrent Breast CancerMetastatic Breast CancerMetastatic Pancreatic Ductal Adenocarcinoma

Phase 1

Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma

Not yet recruitingNCT06981806

Arsen OsipovMetastatic Pancreatic Ductal Adenocarcinoma

Start: 2026-01-31End: 2027-02-28Target: 24Updated: 2025-11-19

Phase 3

Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer

TerminatedNCT03786094

Spexis AGLocally Recurrent Breast Cancer, Metastatic Breast Cancer

Start: 2019-05-30End: 2021-10-19Updated: 2023-11-01

Related Papers

Abstract 414: Efficacy of Balixafortide (POL6326) and Paclitaxel alone and in combination in humanized breast cancer PDX

Cancer Research2021-07-012 citations

Abstract A003: Anti-angiogenic activity of the CXCR4 antagonist balixafortide

Molecular Cancer Therapeutics2019-12-012 citations